# The Presence of Serotonin in the Vestibular System: Supporting the Use of SSRIs/SNRIs in the Treatment of Vestibular Disorders—A Narrative Review

**Authors:** Roberto Teggi, Daniela Caldirola, Giampiero Neri, Iacopo Cangiano, Pasquale Viola, Giuseppe Chiarella

PMC · DOI: 10.3390/audiolres15060148 · Audiology Research · 2025-11-06

## TL;DR

This review explores how serotonin and its receptors may influence vestibular disorders and suggests that SSRIs/SNRIs could be effective treatments.

## Contribution

The paper reviews evidence supporting the role of serotonin in vestibular disorders and the potential use of SSRIs/SNRIs in their treatment.

## Key findings

- SSRIs/SNRIs are used in treating vestibular disorders like PPPD and CSD with multimodal approaches.
- SNRIs and SSRIs reduce vertigo attacks in vestibular migraine and Menière’s Disease.
- Serotonin receptors in the inner ear suggest a link between serotonin levels and vestibular function.

## Abstract

Background: Serotonin (5-HT) is a neurotransmitter and a hormone that regulates various functions. Serotonin receptors have been studied in animal experiments in the vestibular system, beginning from the inner ear and vestibular nuclei. However, the role of serotonin in the vestibular system and disorders remains to be clarified. Methods: A review of the literature was performed on different databases according to the PRISMA guidelines. Only publications published on humans and in English have been included. A total of 41 articles were included in this review. Results: There are many publications regarding the use of SSRI/SNRI in vestibular disorders. Regarding persistent postural perceptual dizziness (PPPD) and chronic subjective dizziness (CSD) the available evidence supports multimodality treatment incorporating vestibular rehabilitation, serotonergic medications, and cognitive behavior therapy, although most studies have not included a placebo control group. As for vestibular migraine (VM), SNRI and SSRIs were proposed as preventive therapy and demonstrated a reduction in vertigo attacks in patients with Menière’s Disease (MD), especially when symptoms of anxiety disorder were present. Conclusions: Although SSRIs/SNRIs are considered an off-label therapy for vertigo, several studies have assessed their efficacy in vestibular disorders, as indicated in the data published on PPPD, MD, and VM above all. As some studies report that serotonin receptors are also present in the inner ear and vestibular nuclei, it can be postulated that in cases where the natural levels of serotonin are altered, such as in depression and anxiety, the change in serotonin levels may affect vestibular function and play a role in vestibular disorders.

## Linked entities

- **Chemicals:** serotonin (PubChem CID 5202)
- **Diseases:** anxiety disorder (MONDO:0005618)

## Full-text entities

- **Diseases:** CSD (MESH:D004244), anxiety (MESH:D001007), MD (MESH:D008575), vertigo (MESH:D014717), anxiety disorder (MESH:D001008), depression (MESH:D003866), Vestibular Disorders (MESH:D015837), VM (MESH:D008881)
- **Chemicals:** 5-HT (MESH:D012701), serotonergic medications (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12641748/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12641748/full.md

## References

43 references — full list in the complete paper: https://tomesphere.com/paper/PMC12641748/full.md

---
Source: https://tomesphere.com/paper/PMC12641748